Bimekizumab - UCB Pharma

Drug Profile

Bimekizumab - UCB Pharma

Alternative Names: Anti-IL-17-mAb-UCB; Anti-IL-17-monoclonal-antibody-UCB; Anti-interleukin-17-monoclonal-antibody-UCB; CDP-4940; UCB-4940

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis; Psoriatic arthritis
  • Phase II Ankylosing spondylitis; Hidradenitis suppurativa; Rheumatoid arthritis; Ulcerative colitis
  • No development reported Psoriasis

Most Recent Events

  • 05 Feb 2018 UCB initiates enrolment in the phase III BE READY trial for Plaque psoriasis in USA (NCT03410992)
  • 26 Jan 2018 UCB plans a phase III BESURE trial for Plaque psoriasis in Jan 2018 (NCT03412747)
  • 26 Jan 2018 UCB initiates enrolment in the phase III BESURE trial for Plaque psoriasis in USA (NCT03412747)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top